Pharmacy Times: Hierarchy of breast cancer cells
UC research pinpoints hierarchy of breast cancer cells as potential cause for treatment resistance
It may take cells in different stages of development to cause breast cancer to progress and spread, according to recent University of Cincinnati research published in the journal eLife.
The findings demonstrated the importance of accounting for specific cell states present in a tumor in order to determine the appropriate combination of drugs necessary to eliminate all the cell states present and halt treatment resistance. The study was led by author Syn Yeo, PhD, research instructor in the department of cancer biology.
Syn Yeo, PhD, research instructor in the department of cancer biology at the UC College of Medicine. Photo by UC Creative + Brand.
He and other researchers noted that the variation between cell states may cause difficulties during treatment if differences in cell states are not accounted for.
"This diversity poses a problem to treating patients because particular subsets of tumor cells may be drug resistant and eventually lead to disease recurrence," says Yeo. "One of the factors contributing to this diversity is the fact that tumor cells can exist in different cellular states, ranging from more stem-like cells that can become other cell types to more differentiated cells that have been coded to serve a purpose, or do a certain 'job' within the system.”
Read the full Pharmacy Times story.
Featured photo of breast cancer cells courtesy of the National Cancer Institute.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
UC enrolls first patients in clinical trial for prosthetic joint infections
April 10, 2026
The University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN clinical trial, testing an investigational drug for prosthetic joint infections after total knee replacement to reduce repeat surgeries and infection recurrence.
A picture-perfect finish for innovation at CEAS EXPO 2026
April 9, 2026
The CEAS EXPO 2026 brought together UC’s brightest engineers to display their forward-thinking projects, with multispectral camera Kromico earning the 1819 Innovation Award.
‘Mini-brain’ shines light on concussions
April 8, 2026
University of Cincinnati biomedical engineers developed a “mini-brain” model to study concussions and traumatic brain injury (TBI) from blunt-force trauma, revealing how cellular damage and inflammation may lead to long-term neurodegenerative disease.